<i>N</i>-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin

Liu, Yun He; D’Ambrosio, Martin A.; Liao, Tang Dong; Peng, Hongmei; Rhaleb, Nour Eddine; Sharma, Umesh C; André, Sabine; Gabius, Hans‐Joachim; Carretero, Oscar A.

doi:10.1152/ajpheart.00747.2008

Cited by 250 publications

(201 citation statements)

References 42 publications

Supporting

Mentioning

184

Contrasting

Unclassified

Order By: Relevance

“…Fibrosis is generally considered to be vital for tissue repair, including cardiac and renal disease [19][20][21][22]. It has been reported that galectin-3 is produced by macrophages and activated myofibroblasts in experimental models of cardiac [23,24], renal [25,26] and liver fibrosis [27].…”

Section: Discussionmentioning

confidence: 99%

The fibrosis marker galectin‐3 and outcome in the general population

Boer¹,

Veldhuisen²,

Gansevoort³

et al. 2011

Journal of Internal Medicine

336

291

View full text Add to dashboard Cite

Abstract. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, Bakker SJL, van der Harst P (University of Groningen). The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012; 272: 55-64.Objective. Galectin-3 is involved in fibrosis and inflammation and plays a role in heart failure, renal disease, obesity and cancer. We aimed to establish the relationship between galectin-3 and cardiovascular (CV) risk factors and mortality in the general population.Design and subjects. This study included 7968 subjects from the Prevention of REnal and Vascular ENd-stage Disease (PREVEND) cohort, with a median follow-up of approximately 10 years. Plasma galectin-3 was measured in baseline samples.Main outcome measures. We investigated the relationships between galectin-3 levels, demographic characteristics and risk factors of CV disease. We determined the prognostic value for all-cause, CV and cancer mortality.Results. The mean age of the population was 50 ± 13 years. Mean blood pressure was 129 ⁄ 74 mmHg, mean cholesterol was 5.7 ± 1.1 mmol L )1 and median galectin-3 was 10.9 ng mL )1 [interquartile range (IQR) 9.0-13.1]. Galectin-3 levels correlated with a wide range of risk factors of CV disease, including blood pressure, serum lipids, body mass index, renal function and N-terminal pro-B-type natriuretic peptide (P < 0.0001). We observed a strong association between galectin-3 and age. Furthermore, we found a gender interaction, with female subjects (n = 4001) having higher median galectin-3 levels (11.0 ng mL )1 , IQR 9.1-13.4 vs. men (n = 3967) 10.7 ng mL )1 , IQR 8.9-12.8; P < 0.0001), and galectin-3 levels in women more strongly correlated with risk factors of CV disease. After correction for the classical CV risk factors (smoking, blood pressure, cholesterol and diabetes), galectin-3 levels independently predicted all-cause mortality (hazard ratio per SD galectin-3 1.09, 95% CI 1.01-1.19; P = 0.036), but not CV and cancer mortality separately.Conclusions. Galectin-3 is associated with age and risk factors of CV disease, with a strong gender interaction for these correlations. Galectin-3 predicts all-cause mortality in the general population.

show abstract

Section: Discussionmentioning

confidence: 99%

The fibrosis marker galectin‐3 and outcome in the general population

Boer¹,

Veldhuisen²,

Gansevoort³

et al. 2011

Journal of Internal Medicine

336

291

View full text Add to dashboard Cite

show abstract

“…Given the observations that Gal-3 has a pivotal role in pathophysiology of adverse cardiac remodeling and it is an independent predictor of HF after ACS, it is reasonable to hypothesize that therapies inhibiting Gal-3 might influence HF progression in high-risk ACS patients [53,54] (Fig. 1).…”

Section: Gal-3 As Target For Therapeutic Strategiesmentioning

confidence: 99%

Galectin-3 in acute coronary syndrome

Agnello

Bivona

Sasso

et al. 2017

Clinical Biochemistry

View full text Add to dashboard Cite

“…The first study to show that galectin-3 in the heart may be inhibited tested intrapericardial infusion of N-acetyl-serylaspartyl-lysyl-proline (Ac-SDKP), a naturally occurring peptide with anti-inflammatory and antifibrotic properties [31,32]. In this study, rats developed cardiac inflammation, fibrosis, and cardiac dysfunction after intrapericardial delivery of galectin-3; however, when AC-SDKP was administered concurrently with galectin-3, these harmful effects were abolished.…”

Section: Galectin-3 As a Therapeutic Targetmentioning

confidence: 88%

Galectin 3: Newest Marker of HF Outcomes

Knight

Xue

Maisel

et al. 2014

Curr Emerg Hosp Med Rep

View full text Add to dashboard Cite

Heart failure is an ever-growing health issue in Western society that affects millions of patients each year. This problem is further exacerbated by high mortality and readmission rates post discharge. Despite recent medical advances, 25 % of patients admitted for heart failure are readmitted within 30 days, and 30 % die within a year. Better risk stratification would decrease such outcomes by identifying patients that require closer follow-up or more aggressive treatment. Galectin-3 is a new heart failure biomarker that has shown great prognostic potential and could aid in such risk stratification. Galectin-3 plays a unique role in the progression of heart failure and is also associated with cardiac remodeling and fibrogenesis, making galectin-3 an effective prognosticator of near and longer term outcomes. This review summarizes the current knowledge about galectin-3 and highlights key studies that demonstrate its prognostic potential. We discuss the potential utility of galectin-3 and suggest that it may be used in conjunction with other heart failure biomarkers. This may provide better risk stratification with the aim of decreasing mortality, healthcare costs, and readmission rates.

show abstract

N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin

Abstract: prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin.

Cited by 250 publications

References 42 publications

The fibrosis marker galectin‐3 and outcome in the general population

The fibrosis marker galectin‐3 and outcome in the general population

Galectin-3 in acute coronary syndrome

Galectin 3: Newest Marker of HF Outcomes

Contact Info

Product

Resources

About